Select Publications

Farley JF, Dusetzina S. (2010) “Medicaid prescription drug utilization and expenditures following Part D.” Journal of Health Care for the Poor and Underserved. (In press).

Wang CC, Farley JF. (2010) “Patterns and predictors of antipsychotic medication use among the U.S. population: Findings from the Medical Expenditure Panel Survey (MEPS).” Research in Social and Administrative Pharmacy. (In Press).

Farley JF. (2010) “Medicaid prescription cost containment and schizophrenia: a retrospective examination.” Medical Care. (In press)

Domino ME, Farley JF. (2010) “Did Medicare Part D improve access to medications?” Psychiatric Services. (In press)

Chen SY, Hansen RA, Farley JF, Gaynes BN, Morrissey JP, Maciejewski ML. (2010) “Provider specialty and follow-up for patients with major depressive disorder treated with antidepressants.” Psychiatric Services. 61(1):81-85.

Dorn SD, Farley JF, Hansen RA, Shah N, Sandler RS. (2009) “The effect of direct to consumer advertisement and physician promotion of tegaserod (Zelnorm) on physician visits, diagnoses, and prescriptions for irritable bowel syndrome and chronic constipation.” Gastroenterology. 137(2):518-524.

Farley JF, Blalock SJ. (2009) “Prescription anti-osteoporosis medication trends and determinants in the U.S. ambulatory population: results from the Medical Expenditure Panel Survey (MEPS).” American Journal of Health-System Pharmacy. 66(1): 1191-1201.

Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA. (2008) “A retrospective examination of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications”.  Clinical Therapeutics. 30(8):1524-1539.

Farley JF, Blalock SJ, Cline RR. (2008) “Effect of the Women’s Health Initiative on prescription anti-osteoporosis medication utilization”. Osteoporosis International. 19(11):1603-1612.